The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women
with steroid hormone receptor positive early invasive breast cancer who receive ovarian
function suppression plus either tamoxifen or exemestane for five years. The use of
chemotherapy was determined by randomization. The method of ovarian function suppression
(GnRH analogue for five years, surgical oophorectomy or ovarian irradiation) and the choice
of tamoxifen or exemestane were determined by the investigator or by randomization in the
IBCSG 25-02 TEXT trial [recommended option]. The trial was terminated early due to poor
accrual.
Phase:
Phase 3
Details
Lead Sponsor:
International Breast Cancer Study Group
Collaborators:
Breast International Group National Cancer Institute (NCI)